MX2022007968A - Dosificacion de gamma-hidroxibutirato (ghb). - Google Patents

Dosificacion de gamma-hidroxibutirato (ghb).

Info

Publication number
MX2022007968A
MX2022007968A MX2022007968A MX2022007968A MX2022007968A MX 2022007968 A MX2022007968 A MX 2022007968A MX 2022007968 A MX2022007968 A MX 2022007968A MX 2022007968 A MX2022007968 A MX 2022007968A MX 2022007968 A MX2022007968 A MX 2022007968A
Authority
MX
Mexico
Prior art keywords
ghb
hydroxybutyrate
dosing
gamma
narcolepsy
Prior art date
Application number
MX2022007968A
Other languages
English (en)
Spanish (es)
Inventor
Franck Skobieranda
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of MX2022007968A publication Critical patent/MX2022007968A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
MX2022007968A 2019-12-24 2020-12-22 Dosificacion de gamma-hidroxibutirato (ghb). MX2022007968A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962953288P 2019-12-24 2019-12-24
US202062993372P 2020-03-23 2020-03-23
US202063000547P 2020-03-27 2020-03-27
US202063052676P 2020-07-16 2020-07-16
PCT/US2020/066561 WO2021133778A1 (en) 2019-12-24 2020-12-22 Gamma-hydroxybutyrate (ghb) dosing

Publications (1)

Publication Number Publication Date
MX2022007968A true MX2022007968A (es) 2022-09-02

Family

ID=74191949

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007968A MX2022007968A (es) 2019-12-24 2020-12-22 Dosificacion de gamma-hidroxibutirato (ghb).

Country Status (14)

Country Link
US (3) US20210186907A1 (https=)
EP (1) EP4081204A1 (https=)
JP (1) JP2023508975A (https=)
KR (1) KR20220119429A (https=)
CN (1) CN115209885A (https=)
AU (1) AU2020414694A1 (https=)
BR (1) BR112022012594A2 (https=)
CA (1) CA3162974A1 (https=)
CL (1) CL2022001743A1 (https=)
CO (1) CO2022010330A2 (https=)
IL (1) IL294176A (https=)
MX (1) MX2022007968A (https=)
TW (1) TW202135790A (https=)
WO (1) WO2021133778A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1140061T3 (da) 1998-12-23 2003-08-25 Orphan Medical Inc Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi
ES2383673T3 (es) 2000-09-22 2012-06-25 Jpi Commercial, Llc Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos
US7610153B2 (en) * 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
CN102946869B (zh) * 2010-05-04 2016-08-03 爵士制药有限公司 γ-羟基丁酸的速释制剂及剂型
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9801852B2 (en) 2013-08-30 2017-10-31 Jazz Pharmaceuticals, Inc. Devices and methods for facilitating and controlling use of a medication
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Also Published As

Publication number Publication date
WO2021133778A1 (en) 2021-07-01
IL294176A (en) 2022-08-01
US20210186907A1 (en) 2021-06-24
JP2023508975A (ja) 2023-03-06
EP4081204A1 (en) 2022-11-02
CO2022010330A2 (es) 2022-10-21
BR112022012594A2 (pt) 2022-09-06
CN115209885A (zh) 2022-10-18
US20240285560A1 (en) 2024-08-29
KR20220119429A (ko) 2022-08-29
AU2020414694A1 (en) 2022-08-18
US20210361601A1 (en) 2021-11-25
TW202135790A (zh) 2021-10-01
CL2022001743A1 (es) 2023-02-10
CA3162974A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
MX2022007968A (es) Dosificacion de gamma-hidroxibutirato (ghb).
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
PH12022551524A1 (en) Irak degraders and uses thereof
PH12021500030A1 (en) Il-2 conjugates and methods of use thereof
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
GEP20237506B (en) Pcsk9 antagonist compounds
MY209474A (en) Il-2 conjugates and methods of use to treat autoimmune diseases
PH12022551522A1 (en) Smarca degraders and uses thereof
PH12020551716A1 (en) Anti-ror antibody constructs
GEP20227443B (en) Magl inhibitors
MX2021015411A (es) Composiciones acopladoras especificas de macrofagos y metodos de uso de las mismas.
EA202190377A1 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
MX2025010681A (es) Formulaciones transdermicas
PH12022550130A1 (en) Enzyme inhibitors
GEP20247585B (en) Furoindazole derivatives
ZA202001756B (en) Oral care compositions
MX2025006782A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina-1 (irak4) y usos de los mismos
EA202191170A1 (ru) Комбинированная терапия для лечения гематологических заболеваний
PH12022551468A1 (en) Compounds active towards nuclear receptors
PH12022550843A1 (en) Thienopyrimidones as trpa1 inhibitors
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
MX2022000811A (es) Inhibidores de enzimas.
MX2024012565A (es) Composiciones farmaceuticas de mosunetuzumab y metodos de uso
PH12022550846A1 (en) Thienopyrimidones as trpa1 inhibitors
MY206426A (en) Anti-cd38 antibodies and formulations